These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 34508005)

  • 1. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.
    Kumar D; Mishra A; Lisok A; Kureshi R; Shelake S; Plyku D; Sen R; Doucet M; De Silva RA; Mease RC; Forde PM; Jaffee EM; Desai P; Ganguly S; Gabrielson E; Vaidya D; Spangler JB; Nimmagadda S
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34508005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
    Kumar D; Lisok A; Dahmane E; McCoy M; Shelake S; Chatterjee S; Allaj V; Sysa-Shah P; Wharram B; Lesniak WG; Tully E; Gabrielson E; Jaffee EM; Poirier JT; Rudin CM; Gobburu JV; Pomper MG; Nimmagadda S
    J Clin Invest; 2019 Feb; 129(2):616-630. PubMed ID: 30457978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
    Kurino T; Matsuda R; Terui A; Suzuki H; Kokubo T; Uehara T; Arano Y; Hisaka A; Hatakeyama H
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive PD-L1 quantification using [
    Mishra A; Gupta K; Kumar D; Lofland G; Sharma AK; Solnes LB; Rowe SP; Forde PM; Pomper MG; Gabrielson EW; Nimmagadda S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.
    Mishra A; Kumar D; Gupta K; Lofland G; Sharma AK; Banka DS; Hobbs RF; Dannals RF; Rowe SP; Gabrielson E; Nimmagadda S
    Clin Cancer Res; 2023 Feb; 29(3):581-591. PubMed ID: 36449662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
    Passariello M; D'Alise AM; Esposito A; Vetrei C; Froechlich G; Scarselli E; Nicosia A; De Lorenzo C
    Sci Rep; 2019 Sep; 9(1):13125. PubMed ID: 31511565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Biologic Evaluation of a Novel
    Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
    J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
    Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
    Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
    Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.
    Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR
    Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
    Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
    Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors.
    Le CT; Murphy WJ
    J Immunother Cancer; 2019 Nov; 7(1):291. PubMed ID: 31699145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.